|
|
|
|
|
|
|
|
|
|
|
 
|
Pancreas Cancer
News and Archives |
|
|
Aphton Announces European Union Granted Orphan Drug Status for G17DT for Pancreatic and Gastric Cancers July 8, 2003 Aphton Corporation announced that the European Union has granted Orphan Drug status for Aphton's anti-gastrin immunogen G17DT, also known as G17(9)DT, for treatment of both pancreatic cancer and gastric (stomach) cancer indications. Orphan Drug status in the European Union confers numerous benefits, including up to ten years of marketing exclusivity, and substantial reduction of fees. This includes a fee reduction of 100% for pre-authorization activities such as protocol assistance (scientific advice) -- and a reduction of 50% for all other fees, including the application for marketing authorization, inspections and post-authorization activities, annual fees etc. ...full article |
||
|
||
|
For educational
purposes only; not to be relied upon Please read Pancreatica Disclaimer |
||
 Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
||
|
|
||
|
www.pancreatica.org |
||